Trv Gp V LLC Takes $261.71 Billion Position in Rapport Therapeutics, Inc. $RAPP

Key Points

• Trv Gp V LLC acquired 6.28 million shares of Rapport Therapeutics, representing a 13.09% stake and about 52.5% of the fund’s portfolio. The filing reported the position’s value as approximately $261.71 billion, although the share count and stock price imply a value closer to $261.7 million.
• Analyst sentiment remains broadly positive: Rapport has a consensus “Buy” rating and an average price target of $62.86, despite one recent “Sell” downgrade.
• RAPP opened at $49.01 after reporting a quarterly loss of $1.19 per share, missing estimates by $0.07. Insiders sold 72,281 shares worth about $3.27 million over the past 90 days.

Trv Gp V LLC acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,280,525 shares of the company's stock, valued at approximately $261,709,477,000. Rapport Therapeutics makes up about 52.5% of Trv Gp V LLC's investment portfolio, making the stock its biggest position. Trv Gp V LLC owned 13.09% of Rapport Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RAPP. KBC Group NV bought a new position in shares of Rapport Therapeutics in the first quarter worth approximately $30,000. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics during the fourth quarter valued at approximately $37,000. Russell Investments Group Ltd. bought a new stake in Rapport Therapeutics during the third quarter valued at approximately $43,000. State of Wyoming purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $65,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock worth $70,000 after buying an additional 905 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RAPP. Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen lowered Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. William Blair initiated coverage on Rapport Therapeutics in a report on Tuesday, July 28th. They set an "outperform" rating on the stock. UBS Group restated a "strong-buy" rating on shares of Rapport Therapeutics in a research report on Monday. Finally, Leerink Partners began coverage on Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Rapport Therapeutics currently has a consensus rating of "Buy" and an average target price of $62.86.

Rapport Therapeutics Price Performance

RAPP opened at $49.01 on Wednesday. The stock's 50 day simple moving average is $41.39 and its 200 day simple moving average is $35.65. The firm has a market cap of $2.35 billion, a price-to-earnings ratio of -16.12 and a beta of 0.97. Rapport Therapeutics, Inc. has a 1 year low of $13.86 and a 1 year high of $49.50.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 EPS for the current year.

Insider Activity at Rapport Therapeutics

In related news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of Rapport Therapeutics stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total value of $743,808.60. Following the transaction, the insider directly owned 6,280,525 shares of the company's stock, valued at $251,535,026.25. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Abraham Ceesay sold 28,958 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer owned 486,108 shares of the company's stock, valued at $23,338,045.08. This represents a 5.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 72,281 shares of company stock worth $3,269,892 in the last 90 days. Company insiders own 12.48% of the company's stock.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

Want to see what other hedge funds are holding RAPP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source